



AQUA BIO TECHNOLOGY ASA

## Aqua Bio Technology ASA: Notifiable transactions in connection with Private Placement

3.8.2023 23:41:55 CEST | Aqua Bio Technology ASA | Mandatory notification of trade primary insiders

Reference is made to the stock exchange announcements made by Aqua Bio Technology ASA ("**ABT**" or the "**Company**") on 23 July 2023 regarding the Company entering into an agreement in principle with the shareholders of Skinteam Norge AS (the "**Sellers**") ("**Skinteam**") and the stock exchange announcements on 23 and 24 July 2023 regarding the Private Placement and the contemplated Subsequent Offering as described therein. Reference is furthermore made to the stock exchange notice earlier today, 3 August 2023, regarding entry into of a final agreement for the Company's acquisition of Skinteam, which also included information on the Company having secured voting undertakings from shareholders representing more than 2/3 of the shares in the Company to where they have undertaken to vote in favour of all resolutions necessary to implement the Private Placement and the contemplated Subsequent Offering in the upcoming extraordinary general meeting (the "**EGM**") that will be held on 24 August 2023.

As a consequence of the voting undertakings, the conditions for completion of the Private Placement will be satisfied and it is therefore considered to correct to disclose the transactions for primary insiders and their close associates at this time. The share capital increase relating to the Private Placement will be approved by an extraordinary general meeting of the Company, to be held on 24 August 2023.

Among the subscribers in the Private Placement were the following primary insiders and close associates of primary insiders in ABT:

- RH Investments AS, a company controlled by Board member Roger Hofseth, has been allocated 4,133,333 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 12,399,999;
- World Heritage Salmon AS, a company controlled by Board member Roger Hofseth, has been allocated 366,666 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 1,099,998;
- Roger Hofseth, Board member, has been allocated 45,833 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 137,500;
- Manville AB, a company controlled by Board member Jan Pettersson, has been allocated 666,666 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 1,999,998;
- Initia AB and Swelandia AB, companies controlled by Board member Jan Pettersson, has been allocated 1,852,691 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 5,558,073;
- Ice Capital AS, a company controlled by CEO Håvard Lindstrøm, has been allocated 183,333 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 549,999;
- Dirigent AS, a company controlled by Per Egil Borge (Chairman of the Board of Skinteam Norge AS) has been allocated 3,058,211 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 9,174,633;
- Face2Face Holding AS, a company controlled by Gun Anita Lyseng (COO of Skinteam Norge AS) has been allocated 716,842 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 2,150,526; and
- Bjørn Sigurd Johansen, Director on the Board of Skinteam Norge AS, has been allocated 1,003,528 new shares in the Private Placement, each at the subscription price of NOK 3.00, for a total subscription amount of NOK 3,010,584.

Please also see the attached notification forms for further information.

For further information, please contact Håvard Lindstrøm, CEO, telephone +47 941 32 288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skin care

products has been, and will continue to be, an important part of the Company's strategy going forward. Aqua Bio Technology is listed on the Euronext Expand market of the Oslo Stock Exchange.

## **Disclosure regulation**

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

## **Contacts**

- Håvard Lindstrøm, 004794132288, [hl@aquabiotech.no](mailto:hl@aquabiotech.no)

## **About Aqua Bio Technology ASA**

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are highly effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users. Aqua Bio Technology is listed on Euronext Expand.

## **Attachments**

- [Download announcement as PDF.pdf](#)
- [Notification form Ice Capital.pdf](#)
- [Notification form Manville.pdf](#)
- [Notification form Roger Hofseth.pdf](#)
- [Notification form Dirigent AS.pdf](#)
- [Notification form Initia Swelandia.pdf](#)
- [Notification form RH Investments AS.pdf](#)
- [Notification form World Heritage Salmon.pdf](#)
- [Notification form Face2Face Holding.pdf](#)
- [Notification form Bjorn Sigurd Johansen.pdf](#)